This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Glynn, J. P. Articles by Kende, M. Search for Related Content PubMed PubMed Citation Articles by Glynn, J. P. Articles by Kende, M.

Treatment of Moloney Virus-induced Leukemia with Cyclophosphamide and Specificially Sensitized Allogeneic Cells¹

Drug Evaluation Branch, Drug Research and Development, Chemotherapy, National Cancer Institute [J. P. G.], and Microbiological Associates, Inc. [M. K.], Bethesda, Maryland 20014

Allogeneic but H-2-compatible spleen cells (DBA/2) were used in conjunction with cyclophosphamide in the treatment of transplantable Moloney virus-induced leukemia of BALB/c mice. Treatment was withheld to within 2 to 6 days of the median survival time of the untreated controls. Cyclophosphamide therapy was followed within 4 to 6 hr by DBA/2 spleen cells either from animals sensitized to Moloney sarcoma virus, C57BL spleen cells, or BALB/c spleen cells or from nonsensitized animals. With Moloney sarcoma virus-sensitized cells, 44/69 animals were long-term survivors, whereas no survivors were obtained with other forms of therapy. All the survivors were stable chimeras as judged by the persistent production of DBA/2 -globulin allotype.

¹ Supported in part by Contract PH-43-68-1283 with Microbiological Associates, Inc.

² Deceased May 7, 1971. Direct reprint requests to M. Kende, Microbiological Associates, Inc., Bethesda Md. 20014.

Received 1/21/71. Accepted 5/20/71.